Christian Karsten Hansen

Last updated

Christian Karsten Hansen (born 18 August 1966) is a Danish biotechnology entrepreneur, investor and inventor, with work in new drugs, molecular biology and biochemistry.

Contents

Personal background

Originally from Copenhagen (Denmark), he spent his childhood in Antwerp, Belgium and Caracas, Venezuela before completing high school at Sorø Academy in 1984. Following graduation as MSc chemical engineering from the Technical University of Denmark in 1989, [1] PhD work in molecular biology and biochemistry was conducted at the Pasteur Institute, [2] [3] [4] France and the University of Salamanca, [5] Spain. He also completed an MBA from the Edinburgh Business School, Scotland. [6]

Professional background

Hansen held positions as senior scientist and director of intellectual property management at Novo Nordisk 1992–1999, and was a member of Enzyme Research Management. [6] He co-founded one of the early Danish biotechnology companies, Profound Pharma, [7] [8] in 1999, with Jan Møller Mikkelsen, [9] and remained co-CEO thereof until its acquisition by Maxygen in 2000. [10] In 2001, he co-founded the investment firm Nordic Biotech Advisors, [1] [11] subsequently renamed NB Capital. [12] [13] [14] [15] [16] [17] [ excessive citations ] Also in 2001, he founded C Hansen Invest.

Since 2001, Hansen has co-founded and/or been a board member of numerous privately held and listed biotechnology companies including Osteologix, [18] [19] Nuevolution, [15] [20] Curalogic, [6] Forward Pharma, [21] Rose Pharma, [22] Poalis, [15] Aditech Pharma, Veloxis Pharmaceuticals, [23] H Pharmaceuticals, Isar Pharma, [24] and ParaTech. [25]

Patents

Hansen has filed numerous patent applications in the fields of genetics of bacteria, cellulases and other enzymes, osteoporosis, and protein engineering and uses of biopharmaceuticals. He is named as inventor of issued European patents 510091, [26] 1250154, [27] 1425304, [28] 1534305, [29] 1622629, [30] 1622630, [31] 1732575, [32] 1745791 [33] 2266584 [34] and 2266585, [35] and US patents 5,843,720, [36] 5,916,796, [37] 6,066,473, [38] 6,555,660, [39] 6,646,110, [40] 6,831,158, [41] 7,230,081, [42] 7,232,562, [43] 7,504,237, [44] 7,550,565, [45] 7,550,566, [46] 7,595,342, [47] 7,696,153 [48] and 8,541,471. [49]

Various compounds from these companies and patents are in mid and late stages of clinical development. [50] [51] [52] [53]

Related Research Articles

Novartis Swiss-American multinational pharmaceutical corporation

Novartis AG is a Swiss-American multinational pharmaceutical corporation based in Basel, Switzerland and Cambridge, Massachusetts, United States. It is one of the largest pharmaceutical companies in the world.

AstraZeneca British-Swedish pharmaceutical company

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It has been involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Yoshiro Nakamatsu Japanese inventor

Yoshiro Nakamatsu, also known as Dr. NakaMats, is a Japanese inventor. He regularly appears on Japanese talk shows demonstrating his inventions.

Valve gear Mechanism for controlling steam flow in a reciprocating steam engine.

The valve gear of a steam engine is the mechanism that operates the inlet and exhaust valves to admit steam into the cylinder and allow exhaust steam to escape, respectively, at the correct points in the cycle. It can also serve as a reversing gear. It is sometimes referred to as the "motion".

Espacenet is a free online service for searching patents and patent applications. Espacenet was developed by the European Patent Office (EPO) together with the member states of the European Patent Organisation. Most member states have an Espacenet service in their national language, and access to the EPO's worldwide database, most of which is in English. In 2015, the Espacenet worldwide service claimed to have records on more than 90 million patent publications.

The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021. India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. It is also the largest vaccine supplier in the world by volume, accounting for more than 50% of all vaccines manufactured in the world. With industry standards compliant mega production capabilities and large number of skilled domestic workforce, Indian exports meet the standards and requirements of highly regulated markets of USA, UK, European Union and Canada. According to the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, domestic pharmaceutical market turnover reached Rs 129,015 crore in 2018, growing 9.4 per cent year-on-year and exports revenue was US$17.28 billion in FY18 and US$19.14 billion in FY19.

Daiichi Sankyo Japanese pharmaceutical company

Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 981.8 billion in revenue in 2019. The company owns the American biotechnology company Plexxikon, American pharmaceutical company American Regent, German biotechnology company U3 Pharma, and recently sold Ranbaxy Laboratories in India. Daiichi Sankyo Co., Ltd. is the producer of Benicar (Olmesartan), an angiotensin II receptor antagonist and top selling drug in the U.S. Global sales of Olmesartan in 2013 were 300.2 billion yen.

Maxygen Inc. was a biopharmaceutical company focused on developing improved versions of protein drugs using DNA shuffling and other protein modification technologies. The company was headquartered in Redwood City, CA. It dissolved in 2013. The Maxygen legacy was revived in 2018 with a focus on Directed Evolution of Proteins using Molecular Breeding. Maxygen LLC is currently headquartered in Sunnyvale, CA.

PainCeptor Pharma is a private Canadian company focused on the development of drugs that act outside the central nervous system on nociceptors to treat pain. The company was established in 2004 through the merger of two academic spinout firms: Antalium from McGill University and NeuroCeptor from Queens University. At its inception, the company's primary operations were in Montreal and Kingston, and it established a partnership with the Danish company NeuroSearch as part of its birth.

WuXi AppTec is a global pharmaceutical, biopharmaceutical, and medical device company.

Harold Holcroft was an English railway and mechanical engineer who worked for the Great Western Railway (GWR), the South Eastern and Chatham Railway (SECR) and the Southern Railway (SR).

Ray Iles Biomedical scientist

Ray Kruse Iles is a biomedical scientist who was head of the Williamson Laboratory for Molecular Oncology at St Bartholomew's Hospital in London.

Cambridge Antibody Technology Defunct British biotechnology company

Cambridge Antibody Technology was a biotechnology company headquartered in Cambridge, England, United Kingdom. Its core focus was on antibody therapeutics, primarily using Phage Display and Ribosome Display technology.

Profound Pharma A/S was a Danish company that develops 2nd generation biopharmaceuticals.

IPS is a screen technology for liquid-crystal displays (LCDs). In IPS, a layer of liquid crystals is sandwiched between two glass surfaces. The liquid crystal molecules are aligned parallel to those surfaces in predetermined directions (in-plane). The molecules are reoriented by an applied electric field, whilst remaining essentially parallel to the surfaces to produce an image. It was designed to solve the strong viewing angle dependence and low-quality color reproduction of the twisted nematic field effect (TN) matrix LCDs prevalent in the late 1980s.

Tralokinumab

Tralokinumab sold under the brand names Adtralza (EU/UK) and Adbry (US) among others, is a human monoclonal antibody used for the treatment of atopic dermatitis. Tralokinumab targets the cytokine interleukin 13.

Sotio

SOTIO Biotech is a Czech biotechnology company focused on clinical-stage research and development of innovative medicines for cancer with operations in Europe, North America, and Asia. The company has clinical programs which include a superagonist of the immuno-oncology target IL-15, a new generation of potent and stable antibody-drug conjugates (ADCs), proprietary technology designed to improve on the efficacy of CAR T therapies and a platform to streamline and enhance personalized cell therapies.

Roivant Sciences is a healthcare company focused on applying technology to drug development. Roivant builds subsidiary biotech and healthcare technology companies. Roivant was founded by Vivek Ramaswamy in 2014.

Relief Therapeutics is a Swiss biopharmaceutical company based in Geneva. The company focuses on developing drugs for serious diseases with few or no existing treatment options. Its lead compound, RLF-100, is a synthetic form of a natural peptide that protects the lung. The company was incorporated as Relief Therapeutics Holdings AG (RFLB.S) and listed on the SIX Swiss Exchange in 2016.

Proprietary drug

Proprietary drug are chemicals used for medicinal purposes which are formulated or manufactured under a name protected from competition through trademark or patent. The invented drug is usually still considered proprietary even if the patent expired. When a patent expires, generic drugs may be developed and released legally. Some international and national governmental organizations have set up laws to enforce intellectual property to protect proprietary drugs, but some also highlight the importance of public health disregarding legal regulations. Proprietary drugs affect the world in various aspects including medicine, public health and economy.

References

  1. 1 2 "Festglad venturekapitalist – Diverse". Business.dk. 10 November 2005. Retrieved 10 November 2011.
  2. ↑ Hansen, C K; Diderichsen, B; Jørgensen, P L (June 1992). "celA from Bacillus lautus PL236 encodes a novel cellulose-binding endo-beta-1,4-glucanase". Journal of Bacteriology. 174 (11): 3522–3531. doi:10.1128/jb.174.11.3522-3531.1992. PMC   206037 . PMID   1592807.
  3. ↑ Jørgensen Per L., Hansen Christian K., Poulsen Gitte B., Diderichsen Børge (1990). "Gene : In vivo genetic engineering: homologous recombination as a tool for plasmid construction". Gene. 96 (1): 37–41. doi:10.1016/0378-1119(90)90338-R. PMID   2265757.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  4. ↑ Jørgensen Per L., Hansen Christian K. (1990). "Gene : Multiple endo-β-1,4-glucanase-encoding genes from Bacillus lactus PL236 and characterization of the celB gene". Gene. 93 (1): 55–60. doi:10.1016/0378-1119(90)90135-E. PMID   2227426.
  5. ↑ Hansen, Christian K. (1992). "FEBS Letters : Fibronectin type III-like sequences and a new domain type in prokaryotic depolymerases with insoluble substrates". FEBS Letters. 305 (2): 91–96. doi: 10.1016/0014-5793(92)80871-D . PMID   1618347. S2CID   33177292.
  6. 1 2 3 "Archived copy" (PDF). Archived from the original (PDF) on 19 July 2011. Retrieved 17 January 2011.{{cite web}}: CS1 maint: archived copy as title (link)
  7. ↑ "Rose Pharma – Board". Gastrotechpharma.com. Archived from the original on 21 November 2008. Retrieved 10 November 2011.
  8. ↑ "Speed, aggression, surprise!". Mva.org. Archived from the original on 28 July 2011. Retrieved 10 November 2011.
  9. ↑ "Dansk bioteks Lance Armstrong – Navne". Business.dk. 3 August 2010. Retrieved 10 November 2011.
  10. ↑ "Maxygen Reports 2000 Third quarter Financial Results. – Free Online Library". Thefreelibrary.com. Retrieved 10 November 2011.
  11. ↑ "Medicon Valley Patent Guide" (PDF). Archived from the original (PDF) on 27 July 2011. Retrieved 17 January 2011.
  12. ↑ "NB Capital". NB Capital. Retrieved 10 November 2011.
  13. ↑ "Vækstfonden – Portefølje". Vf.dk. Retrieved 10 November 2011.
  14. ↑ "European Biotechnology News :: Nordic biotech gets Euro41.5m fund". Eurobiotechnews.eu. Archived from the original on 20 July 2011. Retrieved 10 November 2011.
  15. 1 2 3 "Danish venture capital company Nordic Biotech raises second biotech venture fund (in English)". Mva.org. Archived from the original on 11 September 2011. Retrieved 10 November 2011.
  16. ↑ "Discover Relevant Business Information". venturebeatprofiles.com. Archived from the original on 18 July 2012. Retrieved 17 January 2011.
  17. ↑ Christian Hansen PhD. "NB Capital ApS: Private Company Information – BusinessWeek". Investing.businessweek.com. Retrieved 10 November 2011.
  18. ↑ "2005 Archives". Osteologix. 29 November 2004. Retrieved 10 November 2011.
  19. ↑ "Archived copy" (PDF). Archived from the original (PDF) on 17 March 2012. Retrieved 17 January 2011.{{cite web}}: CS1 maint: archived copy as title (link)
  20. ↑ "Biotech companies in Medicon Valley popular among investors – Invest in Denmark". Investindk.com. 30 October 2007. Retrieved 10 November 2011.
  21. ↑ "Christian Hanse". Forward-pharma.com. Archived from the original on 11 July 2011. Retrieved 10 November 2011.
  22. ↑ "Rose Pharma". Archived from the original on 18 January 2011. Retrieved 14 January 2011.
  23. ↑ "Medicon Valley Financing Guide" (PDF). Archived from the original (PDF) on 27 June 2011. Retrieved 17 January 2011.
  24. ↑ "Isar Pharma K/S: News Release". Marketwire.com. Retrieved 10 November 2011.
  25. ↑ "Board Members | ParaTech". para-tech.dk. Archived from the original on 28 July 2017. Retrieved 28 July 2017.
  26. ↑ "Espacenet – Bibliographic data".
  27. ↑ "espacenet – Bibliographic data". V3.espacenet.com. 23 October 2002. Retrieved 10 November 2011.
  28. ↑ "espacenet – Bibliographic data". V3.espacenet.com. 9 June 2004. Retrieved 10 November 2011.
  29. ↑ "espacenet – Original document". V3.espacenet.com. Retrieved 10 November 2011.
  30. ↑ "Espacenet – Bibliographic data".
  31. ↑ "Espacenet – Bibliographic data".
  32. ↑ "espacenet – Bibliographic data". V3.espacenet.com. 20 December 2006. Retrieved 10 November 2011.
  33. ↑ "Espacenet – Bibliographic data".
  34. ↑ "Espacenet – Bibliographic data".
  35. ↑ "Espacenet – Bibliographic data".
  36. ↑ "Introduction of DNA into bacillus strains by conjugation – US Patent 5843720 Description". Patentstorm.us. Archived from the original on 11 October 2012. Retrieved 10 November 2011.
  37. ↑ "Enzyme exhibiting cellulase activity – US Patent 5916796 Full Text". Patentstorm.us. Archived from the original on 11 October 2012. Retrieved 10 November 2011.
  38. ↑ "Introduction of DNA into bacillus strains by conjugation – US Patent 6066473 Description". Patentstorm.us. Archived from the original on 11 October 2012. Retrieved 10 November 2011.
  39. ↑ "G-CSF conjugates – US Patent 6555660 Full Text". Patentstorm.us. Archived from the original on 11 October 2012. Retrieved 10 November 2011.
  40. ↑ "G-CSF polypeptides and conjugates – US Patent 6646110 Full Text". Patentstorm.us. Archived from the original on 11 October 2012. Retrieved 10 November 2011.
  41. ↑ "G-CSF conjugates – US Patent 6831158 Full Text". Patentstorm.us. Archived from the original on 11 October 2012. Retrieved 10 November 2011.
  42. ↑ "Interferon gamma conjugates – US Patent 7230081 Full Text". Patentstorm.us. Archived from the original on 11 October 2012. Retrieved 10 November 2011.
  43. ↑ "E38N interferon gamma polypeptide variants – US Patent 7232562 Full Text". Patentstorm.us. Archived from the original on 11 October 2012. Retrieved 10 November 2011.
  44. ↑ "Polynucleotides encoding interferon gamma polypeptides – US Patent 7504237 Full Text". Patentstorm.us. Archived from the original on 11 October 2012. Retrieved 10 November 2011.
  45. ↑ "G-CSF conjugates – US Patent 7550565 Full Text". Patentstorm.us. Archived from the original on 11 October 2012. Retrieved 10 November 2011.
  46. ↑ "G-CSF conjugates – US Patent 7550566 Full Text". Patentstorm.us. Archived from the original on 11 October 2012. Retrieved 10 November 2011.
  47. ↑ "Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions – US Patent 7595342 Full Text". Patentstorm.us. Archived from the original on 11 October 2012. Retrieved 10 November 2011.
  48. ↑ "G-CSF conjugates – US Patent 7696153 Full Text". Patentstorm.us. Archived from the original on 11 October 2012. Retrieved 10 November 2011.
  49. ↑ "Water-soluble strontium salts for use in treatment of cartilage and/Or bone conditions - US Patent 8541471 Full Text". www.patentstorm.us. Archived from the original on 27 September 2013. Retrieved 6 June 2022.
  50. ↑ "News". Osteologix. 30 March 2009. Retrieved 10 November 2011.
  51. ↑ Clinical trial number NCT00409032 for "A Dose-response Study With Strontium Malonate in Postmenopausal Women" at ClinicalTrials.gov
  52. ↑ "Treatment of Neutropenia, G-CSF, Neutrophils, Chemotherapy, Protein Therapeutics, Pegylated, Clinical Trial, Neupogen, Neulasta, Blood, Bone Marrow, Breast cancer, Lung cancer, Lymphomas, Leukemias". Maxygen.com. Archived from the original on 12 October 2011. Retrieved 10 November 2011.
  53. ↑ Clinical trial number NCT00501332 for "Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Chemotherapy" at ClinicalTrials.gov
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.